NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
2.00
Dollar change
-0.04
Percentage change
-1.96
%
Index- P/E- EPS (ttm)-1.58 Insider Own9.53% Shs Outstand28.32M Perf Week-2.44%
Market Cap58.32M Forward P/E- EPS next Y-1.69 Insider Trans0.00% Shs Float26.38M Perf Month-16.32%
Enterprise Value-28.53M PEG- EPS next Q-0.47 Inst Own45.99% Short Float1.81% Perf Quarter-16.32%
Income-47.30M P/S83.31 EPS this Y8.08% Inst Trans-4.10% Short Ratio3.14 Perf Half Y-28.83%
Sales0.70M P/B0.70 EPS next Y-10.10% ROA-42.35% Short Interest0.48M Perf YTD-32.20%
Book/sh2.86 P/C0.66 EPS next 5Y29.31% ROE-46.28% 52W High4.21 -52.49% Perf Year-43.98%
Cash/sh3.04 P/FCF- EPS past 3/5Y39.12% 35.63% ROIC-57.53% 52W Low1.90 5.26% Perf 3Y-92.67%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-24.04% - Gross Margin11.86% Volatility4.42% 6.26% Perf 5Y-87.16%
Dividend TTM- EV/Sales-40.76 EPS Y/Y TTM54.91% Oper. Margin-7566.52% ATR (14)0.13 Perf 10Y-99.17%
Dividend Ex-Date- Quick Ratio9.35 Sales Y/Y TTM-33.00% Profit Margin-6774.22% RSI (14)39.12 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.35 EPS Q/Q-112.31% SMA20-7.61% Beta0.37 Target Price12.00
Payout- Debt/Eq0.02 Sales Q/Q-43.12% SMA50-12.50% Rel Volume0.70 Prev Close2.04
Employees57 LT Debt/Eq0.01 EarningsJun 17 AMC SMA200-24.57% Avg Volume152.25K Price2.00
IPOJun 21, 2011 Option/ShortYes / Yes EPS/Sales Surpr.13.43% -102.39% Trades Volume107,238 Change-1.96%
Date Action Analyst Rating Change Price Target Change
Dec-07-23Upgrade Jefferies Hold → Buy $15
Aug-07-23Upgrade Maxim Group Hold → Buy $30
Jul-22-22Downgrade William Blair Outperform → Mkt Perform
Jul-22-22Downgrade Robert W. Baird Outperform → Neutral
Jul-22-22Downgrade Jefferies Buy → Hold
May-20-21Initiated Robert W. Baird Outperform $9
Feb-18-21Initiated Jefferies Buy $6
Jan-04-21Upgrade William Blair Mkt Perform → Outperform
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Jul-02-25 10:03PM
Jun-25-25 08:30AM
Jun-18-25 03:01AM
Jun-17-25 04:30PM
05:20AM
04:11AM Loading…
04:11AM
Jun-16-25 09:16AM
Jun-12-25 08:30AM
Jun-02-25 08:30AM
May-28-25 08:30AM
May-23-25 08:30AM
May-15-25 09:15AM
May-14-25 05:35PM
May-13-25 05:15PM
May-12-25 05:10PM
08:30AM Loading…
Apr-17-25 08:30AM
Mar-19-25 08:30AM
Mar-04-25 08:30AM
Feb-20-25 08:30AM
Feb-14-25 02:22AM
Feb-13-25 05:55PM
04:30PM
Feb-12-25 07:51AM
Feb-06-25 08:30AM
Feb-05-25 08:30AM
Jan-15-25 05:16AM
Jan-14-25 08:30AM
Jan-10-25 08:30AM
Nov-14-24 08:30AM
Nov-08-24 02:31AM
07:30PM Loading…
Nov-07-24 07:30PM
04:20PM
Nov-06-24 07:51AM
Nov-05-24 08:30AM
Nov-01-24 08:30AM
Oct-11-24 12:00PM
Oct-09-24 06:20PM
08:30AM
Sep-24-24 04:52AM
Sep-23-24 08:30AM
Sep-06-24 12:00PM
Aug-13-24 05:30PM
04:21PM
Aug-06-24 08:30AM
Jul-26-24 06:20AM
Jul-10-24 06:33AM
Jul-09-24 08:30AM
Jun-27-24 08:30AM
Jun-12-24 08:52AM
08:02AM
Jun-11-24 04:20PM
Jun-07-24 08:30AM
May-29-24 08:30AM
May-23-24 08:30AM
May-14-24 06:59AM
May-13-24 10:00AM
May-07-24 08:30AM
Apr-25-24 08:30AM
Apr-19-24 07:13AM
Apr-09-24 01:28PM
08:30AM
Apr-01-24 08:30AM
Mar-31-24 10:00AM
Mar-26-24 06:24AM
Mar-11-24 08:30AM
Feb-28-24 08:30AM
Feb-21-24 09:55AM
Feb-19-24 12:24PM
Feb-15-24 08:20AM
Feb-14-24 03:45PM
Feb-13-24 04:59PM
04:20PM
Feb-07-24 07:38AM
Feb-06-24 08:30AM
Jan-26-24 09:04AM
Dec-29-23 08:40AM
Dec-27-23 08:30AM
Dec-20-23 02:15PM
Nov-11-23 01:03PM
Nov-09-23 04:30PM
Nov-08-23 08:30AM
Nov-07-23 08:30AM
Nov-06-23 08:00AM
Oct-05-23 08:30AM
Oct-02-23 07:30AM
Sep-21-23 04:43PM
Sep-12-23 08:30AM
Sep-05-23 09:00AM
Aug-22-23 08:30AM
Aug-15-23 07:37AM
Aug-11-23 10:34AM
Aug-10-23 04:21PM
10:31AM
03:49AM
Aug-08-23 04:30PM
Aug-07-23 05:46PM
04:12PM
08:30AM
Jul-17-23 08:00AM
Jul-13-23 04:05PM
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.